The efficacy of this combinatorial regimen on BRAF-mutant CRC was confirmed in an additional BRAF-mutant CRC cell line (SNUC5), in which inclusion of pevonedistat significantly reduced relative growth (p ≤ 0.01) and number of colonies (p ≤ 0.01) induced by vemurafenib plus cetuximab (Figure S2C,D). The gene discussed is BRAF; the disease is colorectal carcinoma.